Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD201 versus Herceptin in HER2-positive early breast cancer
2016-004019-11Phase 3Completed
- Sponsor
- Prestige Biopharma Limited
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of coprelotamab in breast cancer (2 arms), sponsored by Prestige Biopharma Limited. Primary endpoint: Total pathological complete response rate. Started Dec 2017; status: completed.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004019-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004019-11.